Kezar Life Sciences, Inc. KZR 73.38%
shares shot up 98% to $8.86 after the company announced updated results
from the Phase 1b portion of the Phase 1b/2 MISSION study, which is
evaluating the safety and tolerability of KZR-616 in patients with
systemic lupus erythematosus with and without nephritis, showing overall
improvements across seven measures of disease activity.
https://www.benzinga.com/news/earnings/20/06/16181816/mid-day-market-update-smartsheet-drops-on-weak-guidance-kezar-life-sciences-shares-climb
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.